Clinical characteristics and outcomes of thymoma-associated myasthenia gravis.
myasthenia gravis
prognosis
recurrence
thymoma
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
26
02
2021
received:
07
02
2021
accepted:
10
03
2021
pubmed:
16
3
2021
medline:
13
8
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG. This multicenter study was based on data from a Spanish neurologist-driven MG registry. All patients were aged >18 years at onset and had anti-acetylcholine receptor antibodies. We compared the clinical data of thymomatous and nonthymomatous patients. Prognosis of patients with recurrent or nonresectable thymomas was assessed. We included 964 patients from 15 hospitals; 148 (15.4%) had thymoma-associated MG. Median follow-up time was 4.6 years. At onset, thymoma-associated MG patients were younger (52.0 vs. 60.4 years, p < 0.001), had more generalized symptoms (odds ratio [OR]: 3.02, 95% confidence interval [CI]: 1.95-4.68, p < 0.001) and more severe clinical forms according to the Myasthenia Gravis Foundation of America (MGFA) scale (OR: 1.6, 95% CI: 1.15-2.21, p = 0.005). Disease severity based on MGFA postintervention status (MGFA-PIS) was higher in thymomatous patients at 1 year, 5 years, and the end of follow-up. Treatment refractoriness and mortality were also higher (OR: 2.28, 95% CI: 1.43-3.63, p = 0.001; hazard ratio: 2.46, 95% CI: 1.47-4.14, p = 0.001). Myasthenic symptoms worsened in 13 of 27 patients with recurrences, but differences in long-term severity were not significant. Fifteen thymomatous patients had nonresectable thymomas with worse MGFA-PIS and higher mortality at the end of follow-up. Thymoma-associated MG patients had more severe myasthenic symptoms and worse prognosis. Thymoma recurrence was frequently associated with transient worsening of MG, but long-term prognosis did not differ from nonrecurrent thymoma. Patients with nonresectable thymoma tended to present severe forms of MG.
Sections du résumé
BACKGROUND AND PURPOSE
Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.
METHODS
This multicenter study was based on data from a Spanish neurologist-driven MG registry. All patients were aged >18 years at onset and had anti-acetylcholine receptor antibodies. We compared the clinical data of thymomatous and nonthymomatous patients. Prognosis of patients with recurrent or nonresectable thymomas was assessed.
RESULTS
We included 964 patients from 15 hospitals; 148 (15.4%) had thymoma-associated MG. Median follow-up time was 4.6 years. At onset, thymoma-associated MG patients were younger (52.0 vs. 60.4 years, p < 0.001), had more generalized symptoms (odds ratio [OR]: 3.02, 95% confidence interval [CI]: 1.95-4.68, p < 0.001) and more severe clinical forms according to the Myasthenia Gravis Foundation of America (MGFA) scale (OR: 1.6, 95% CI: 1.15-2.21, p = 0.005). Disease severity based on MGFA postintervention status (MGFA-PIS) was higher in thymomatous patients at 1 year, 5 years, and the end of follow-up. Treatment refractoriness and mortality were also higher (OR: 2.28, 95% CI: 1.43-3.63, p = 0.001; hazard ratio: 2.46, 95% CI: 1.47-4.14, p = 0.001). Myasthenic symptoms worsened in 13 of 27 patients with recurrences, but differences in long-term severity were not significant. Fifteen thymomatous patients had nonresectable thymomas with worse MGFA-PIS and higher mortality at the end of follow-up.
CONCLUSIONS
Thymoma-associated MG patients had more severe myasthenic symptoms and worse prognosis. Thymoma recurrence was frequently associated with transient worsening of MG, but long-term prognosis did not differ from nonrecurrent thymoma. Patients with nonresectable thymoma tended to present severe forms of MG.
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2083-2091Informations de copyright
© 2021 European Academy of Neurology.
Références
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023-1036. https://doi.org/10.1016/S1474-4422(15)00145-3
Hoch W, Mcconville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365-368. https://doi.org/10.1038/85520
Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69:418-422. https://doi.org/10.1002/ana.22312
Gallardo E, Martínez-Hernández E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014;13:1003-1007. https://doi.org/10.1016/j.autrev.2014.08.039
Santos E, Bettencourt A, Duarte S, et al. Refractory myasthenia gravis: Characteristics of a Portuguese cohort. Muscle Nerve. 2019;60(2):188-191. https://doi.org/10.1002/mus.26507
Na KJ, Hyun K, Kang CH, et al. Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database. Eur J Cardio-Thoracic Surg. 2020;57:867-873. https://doi.org/10.1093/ejcts/ezz334
Budde JM, Morris CD, Gal AA, et al. Predctors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg. 2001;72:197-202. https://doi.org/10.1016/S0003-4975(01)02678-9
Kaufman AJ, Palatt J, Sivak M, et al. Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg. 2016;28:561-568. https://doi.org/10.1053/j.semtcvs.2016.04.002
Tsinzerling N, Lefvert AK, Matell G, et al. Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J Neurol Neurosurg Psychiatry. 2007;78:1109-1112. https://doi.org/10.1136/jnnp.2006.109488
Beghi E, Antozzi C, Batocchi AP, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci. 1991;106:213-220. https://doi.org/10.1016/0022-510X(91)90260-E
Shen J, Tie H, Xu A, et al. Inter-relationship among myasthenia gravis, WHO histology, and Masaoka clinical stage and effect on surgical methods in patients with thymoma: a retrospective cohort study. J Thorac Dis. 2018;10:2981-2990. https://doi.org/10.21037/jtd.2018.05.30
Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol. 2001;25:103-110. https://doi.org/10.1097/00000478-200101000-00012
Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-2492. https://doi.org/10.1002/1097-0142(19811201)48:11<2485:AID-CNCR2820481123>3.0.CO;2-R
Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;76:878-884. https://doi.org/10.1016/S0003-4975(03)00555-1
Moser B, Fadel E, Fabre D, et al. Surgical therapy of thymic tumours with pleural involvement: An ESTS Thymic Working Group Project. Eur J Cardio-thoracic Surg. 2017;52:346-355. https://doi.org/10.1093/ejcts/ezx090
Huang J, Detterbeck FC, Wang Z, et al. Standard outcome measures for thymic malignancies. J Thorac Oncol. 2010;5:2017-2023. https://doi.org/10.1097/JTO.0b013e3181f13682
Sanders DB, Wolfe GI, Narayanaswami P. Editors' note. Neurology. 2017;88:505.1. https://doi.org/10.1212/WNL.0000000000003574
Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70:327-334.
Mao Z-F, Mo X-A, Qin C, et al. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol. 2010;17:913-921. https://doi.org/10.1111/j.1468-1331.2010.03017.x
Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, hla antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103:579-601. https://doi.org/10.1093/brain/103.3.579
Robertson NP, Deans J, Compston DAS. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry. 1998;65:492-496. https://doi.org/10.1136/jnnp.65.4.492
Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94:e1171-e1180. https://doi.org/10.1212/WNL.0000000000008903
Westerberg E, Punga AR. Mortality rates and causes of death in Swedish Myasthenia Gravis patients. Neuromuscul Disord. 2020;30:815-824. https://doi.org/10.1016/j.nmd.2020.08.355
Kamata T, Yoshida S, Wada H, et al. Extrathymic malignancies associated with thymoma: a forty-year experience at a single institution. Interact Cardiovasc Thorac Surg. 2016;24:ivw354. https://doi.org/10.1093/icvts/ivw354
Filosso PL, Galassi C, Ruffini E, et al. Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. Eur J Cardio-thoracic Surg. 2013;44:219-224. https://doi.org/10.1093/ejcts/ezs663
Kim H, Lim Y-M, Lee E-J, et al. Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis. Muscle Nerve. 2018;58:796-800. https://doi.org/10.1002/mus.26300
de Perrot M, Liu J, Bril V, et al. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg. 2002;74:1658-1662. https://doi.org/10.1016/S0003-4975(02)04083-3
Akaishi T, Suzuki Y, Imai T, et al. Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol. 2016;16:225. https://doi.org/10.1186/s12883-016-0756-3
Tian W, Li X, Tong H, et al. Surgical effect and prognostic factors of myasthenia gravis with thymomas. Thorac Cancer. 2020;11:1288-1296. https://doi.org/10.1111/1759-7714.13396
Maggi L, Andreetta F, Antozzi C, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol. 2008;201-202:237-244. https://doi.org/10.1016/j.jneuroim.2008.07.012